Get the Stockscreener App
47.18
0.64%
0.30
After Hours:
47.17
-0.010
-0.02%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $47.18, with a volume of 10.69M.
It is up +0.64% in the last 24 hours and up +0.68% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$46.88
Open:
$46.99
24h Volume:
10.69M
Relative Volume:
0.85
Market Cap:
$96.03B
Revenue:
$47.70B
Net Income/Loss:
$5.07B
P/E Ratio:
19.02
EPS:
2.48
Net Cash Flow:
$14.58B
1W Performance:
-1.54%
1M Performance:
+0.68%
6M Performance:
-19.76%
1Y Performance:
-5.11%
1-Day Range:
$46.82
$47.36
1-Week Range:
$46.65
$48.15
52-Week Range:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
47.18 | 95.42B | 47.70B | 5.07B | 14.58B | 2.48 |
|
LLY
Lilly Eli Co
|
732.58 | 656.17B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.17 | 422.54B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.40 | 367.30B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.55 | 244.83B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.12 | 207.84B | 63.43B | 16.42B | 14.72B | 6.49 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb Company Equity Right’s volatility index tracking explained2025 Market Outlook & Risk Managed Investment Signals - Newser
Is it time to cut losses on Bristol Myers Squibb Company Equity RightJuly 2025 Recap & Free Fast Gain Swing Trade Alerts - Newser
How to interpret RSI for Bristol Myers Squibb Company stockEarnings Risk Report & Fast Gain Stock Tips - Newser
Using data tools to time your Bristol Myers Squibb Company Equity Right exit2025 Key Lessons & Reliable Breakout Forecasts - Newser
Risk vs reward if holding onto Bristol Myers Squibb Company Equity Right2025 Momentum Check & Low Risk High Win Rate Picks - Newser
Key resistance and support levels for Bristol Myers Squibb CompanyEarnings Growth Summary & Long-Term Safe Return Strategies - Newser
Healthcare Is Sickly but These Dividend Yields up to 7% May Still Have a Pulse - Investing.com
Layoff Tracker: Exelixis Cuts Go Beyond Pennsylvania, Include 71 at California HQ - BioSpace
Price action breakdown for Bristol Myers Squibb CompanyJuly 2025 Earnings & Safe Swing Trade Setups - Newser
Can momentum traders help lift Bristol Myers Squibb CompanyWeekly Market Outlook & Momentum Based Trading Ideas - Newser
What MACD signals say about Bristol Myers Squibb Company Equity RightMarket Sentiment Review & Fast Gain Stock Trading Tips - Newser
News impact scoring models applied to Bristol Myers Squibb CompanyEarnings Risk Summary & Daily Technical Forecast Reports - Newser
Real time social sentiment graph for Bristol Myers Squibb CompanyWeekly Risk Summary & AI Optimized Trading Strategy Guides - Newser
How to track smart money flows in Bristol Myers Squibb Company Equity RightJuly 2025 Update & AI Driven Price Predictions - Newser
Chart based exit strategy for Bristol Myers Squibb CompanyJuly 2025 Recap & Capital Protection Trade Alerts - Newser
Chart based analysis of Bristol Myers Squibb Company Equity Right trendsWeekly Investment Summary & Growth Oriented Trade Recommendations - Newser
Should you wait for a breakout in Bristol Myers Squibb CompanyJuly 2025 Opening Moves & Capital Protection Trade Alerts - Newser
Can Bristol Myers Squibb Company lead its sector in growth getLinesFromResByArray error: size == 0 - mustnews.co.kr
Discovery of dual molecular glue degrader BMS-986470 - BioWorld MedTech
What momentum shifts mean for Bristol Myers Squibb CompanyWeekly Market Outlook & Free Weekly Watchlist of Top Performers - Newser
Can Bristol Myers Squibb Company hit a new high this month2025 Buyback Activity & Expert Verified Stock Movement Alerts - Newser
Cantor Fitzgerald Cuts Bristol-Myers (BMY) Price Target, Keeps Neutral - Insider Monkey
Will Camzyos Strengthen BMY's Cardiovascular Portfolio? - Yahoo Finance
What data driven models say about Bristol Myers Squibb Company Equity Right’s futureJuly 2025 Highlights & Fast Moving Market Watchlists - Newser
Order flow analysis tools used on Bristol Myers Squibb Company Equity RightMarket Movement Recap & Step-by-Step Trade Execution Guides - Newser
Signal strength of Bristol Myers Squibb Company stock in tech scannersJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - Newser
Analyzing Bristol Myers Squibb Company with multi timeframe chartsPortfolio Performance Report & Daily Volume Surge Trade Alerts - Newser
Is Bristol Myers Squibb Company stock bottoming outWeekly Trend Report & AI Powered Market Entry Ideas - Newser
Earnings visualization tools for Bristol Myers Squibb CompanyWeekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - Newser
Published on: 2025-08-26 17:49:14 - beatles.ru
Using Ichimoku Cloud for Bristol Myers Squibb Company Equity Right technicalsJuly 2025 Summary & Low Drawdown Trading Strategies - Newser
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Our science - Bristol Myers Squibb
Is Bristol Myers Squibb Company impacted by rising rates2025 Price Action Summary & Daily Stock Trend Watchlist - theviewers.co.kr
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now? - Yahoo Finance
Career oncologist makes Big Pharma leap to BMS—Chutes & Ladders - fiercebiotech.com
ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Lilly neuro exec Anne White to retire; Bristol Myers fills new medical affairs position - Endpoints News
The Escalator: Bristol Myers Squibb, Eli Lilly, Stephen Hahn and more - Medical Marketing and Media
Agilent, Bristol Myers win FDA nod for cancer test (A:NYSE) - Seeking Alpha
Bristol Myers Squibb Stock Surges on FDA Breakthrough Designation for Lung Cancer Drug Despite Ranking 217th in Trading Volume - AInvest
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan... - Medical Dialogues
Bristol Myers Squibb's Lung Cancer Drug Secures FDA Breakthrough Status - AInvest
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Yahoo Finance
Bristol Myers Squibb Company stock outlook for YEAR2025 Volume Leaders & AI Driven Stock Movement Reports - Newser
Israel issues first antitrust fine to a global pharmaceutical company - Global Competition Review
FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb - Enidnews.com
Bristol Myers and SystImmune’s lung cancer drug gets FDA boost - Investing.com
The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific - Yahoo Finance
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.92%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):